Skip to content 
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. more
| Time Frame | MESO | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 0.12% | 1.07% | 0.74% |
| 1-Month Return | 0.48% | 1.46% | 1.28% |
| 3-Month Return | 13.87% | 3.51% | 3.6% |
| 6-Month Return | 11.69% | 15.29% | 7.31% |
| 1-Year Return | -2.93% | 7.7% | 11.97% |
| 3-Year Return | 160.15% | 21.02% | 72.07% |
| 5-Year Return | -17.91% | 37.81% | 76.01% |
| 10-Year Return | 65.1% | 139.15% | 258.47% |
| Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 7.46M | 10.21M | 7.50M | 5.90M | 17.20M | [{"date":"2021-06-30","value":43.35,"profit":true},{"date":"2022-06-30","value":59.37,"profit":true},{"date":"2023-06-30","value":43.62,"profit":true},{"date":"2024-06-30","value":34.32,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] |
| Cost of Revenue | 85.73M | 63.57M | 54.92M | 41.07M | 5.13M | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":74.15,"profit":true},{"date":"2023-06-30","value":64.06,"profit":true},{"date":"2024-06-30","value":47.91,"profit":true},{"date":"2025-06-30","value":5.98,"profit":true}] |
| Gross Profit | (78.28M) | (53.36M) | (47.42M) | (35.17M) | 12.07M | [{"date":"2021-06-30","value":-648.62,"profit":false},{"date":"2022-06-30","value":-442.17,"profit":false},{"date":"2023-06-30","value":-392.95,"profit":false},{"date":"2024-06-30","value":-291.42,"profit":false},{"date":"2025-06-30","value":100,"profit":true}] |
| Gross Margin | (1049.83%) | (522.58%) | (632.20%) | (595.87%) | 70.17% | [{"date":"2021-06-30","value":-1496.1,"profit":false},{"date":"2022-06-30","value":-744.73,"profit":false},{"date":"2023-06-30","value":-900.94,"profit":false},{"date":"2024-06-30","value":-849.16,"profit":false},{"date":"2025-06-30","value":100,"profit":true}] |
| Operating Expenses | 115.06M | 90.78M | 76.79M | 48.98M | 74.51M | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":78.9,"profit":true},{"date":"2023-06-30","value":66.74,"profit":true},{"date":"2024-06-30","value":42.57,"profit":true},{"date":"2025-06-30","value":64.76,"profit":true}] |
| Operating Income | (109.10M) | (80.57M) | (69.29M) | (84.15M) | (62.44M) | [{"date":"2021-06-30","value":-10909600000,"profit":false},{"date":"2022-06-30","value":-8057400000,"profit":false},{"date":"2023-06-30","value":-6928900000,"profit":false},{"date":"2024-06-30","value":-8414700000,"profit":false},{"date":"2025-06-30","value":-6244300000,"profit":false}] |
| Total Non-Operating Income/Expense | (1.25M) | (27.76M) | (32.10M) | (22.83M) | (58.37M) | [{"date":"2021-06-30","value":-124800000,"profit":false},{"date":"2022-06-30","value":-2776400000,"profit":false},{"date":"2023-06-30","value":-3210300000,"profit":false},{"date":"2024-06-30","value":-2283400000,"profit":false},{"date":"2025-06-30","value":-5836700000,"profit":false}] |
| Pre-Tax Income | (99.63M) | (91.59M) | (82.10M) | (88.15M) | (101.81M) | [{"date":"2021-06-30","value":-9963000000,"profit":false},{"date":"2022-06-30","value":-9158600000,"profit":false},{"date":"2023-06-30","value":-8210100000,"profit":false},{"date":"2024-06-30","value":-8814700000,"profit":false},{"date":"2025-06-30","value":-10181200000,"profit":false}] |
| Income Taxes | (819.00K) | (239.00K) | (212.00K) | (191.00K) | 330.00K | [{"date":"2021-06-30","value":-248.18,"profit":false},{"date":"2022-06-30","value":-72.42,"profit":false},{"date":"2023-06-30","value":-64.24,"profit":false},{"date":"2024-06-30","value":-57.88,"profit":false},{"date":"2025-06-30","value":100,"profit":true}] |
| Income After Taxes | (98.81M) | (91.35M) | (81.89M) | (87.96M) | (102.14M) | [{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false},{"date":"2025-06-30","value":-10214200000,"profit":false}] |
| Income From Continuous Operations | (98.81M) | (91.35M) | (81.89M) | (87.96M) | (102.14M) | [{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false},{"date":"2025-06-30","value":-10214200000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] |
| Net Income | (98.81M) | (91.35M) | (81.89M) | (87.96M) | (102.14M) | [{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false},{"date":"2025-06-30","value":-10214200000,"profit":false}] |
| EPS (Diluted) | (0.82) | (0.70) | (0.55) | (0.13) | (0.36) | [{"date":"2021-06-30","value":-82,"profit":false},{"date":"2022-06-30","value":-70,"profit":false},{"date":"2023-06-30","value":-54.74,"profit":false},{"date":"2024-06-30","value":-13.17,"profit":false},{"date":"2025-06-30","value":-36,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| MESO | |
|---|---|
| Cash Ratio | 1.57 |
| Current Ratio | 1.99 |
| Quick Ratio | 1.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| MESO | |
|---|---|
| ROA (LTM) | -5.37% |
| ROE (LTM) | -18.95% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| MESO | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| MESO | |
|---|---|
| Trailing PE | NM |
| Forward PE | 454.55 |
| P/S (TTM) | 130.00 |
| P/B | 3.60 |
| EV/R | 123.25 |
| EV/Ebitda | NM |
| PEG | NM |
Mesoblast Ltd (MESO) share price today is $16.91
Yes, Indians can buy shares of Mesoblast Ltd (MESO) on Vested. To buy
Yes, you can purchase fractional shares of Mesoblast Ltd (MESO) via the Vested app. You can start investing in Mesoblast Ltd (MESO) with a minimum investment of $1.
You can invest in shares of Mesoblast Ltd (MESO) via Vested in three simple steps:
The 52-week high price of Mesoblast Ltd (MESO) is $21.5. The 52-week low price of Mesoblast Ltd (MESO) is $9.61.
The price-to-earnings (P/E) ratio of Mesoblast Ltd (MESO) is
The price-to-book (P/B) ratio of Mesoblast Ltd (MESO) is 3.60
The dividend yield of Mesoblast Ltd (MESO) is 0.00%
The market capitalization of Mesoblast Ltd (MESO) is $2.20B
The stock symbol (or ticker) of Mesoblast Ltd is MESO
Consider the share price of Mesoblast Ltd as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Mesoblast Ltd has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Mesoblast Ltd shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Mesoblast Ltd stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Mesoblast Ltd and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Mesoblast Ltd stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
